Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Equity Average (2020 - 2025)

Historic Equity Average for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to $210.2 million.

  • Pliant Therapeutics' Equity Average fell 4307.54% to $210.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.2 million, marking a year-over-year decrease of 4307.54%. This contributed to the annual value of $388.8 million for FY2024, which is 117.69% down from last year.
  • According to the latest figures from Q3 2025, Pliant Therapeutics' Equity Average is $210.2 million, which was down 4307.54% from $238.6 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Equity Average ranged from a high of $547.5 million in Q2 2023 and a low of $160.8 million during Q2 2022
  • Its 5-year average for Equity Average is $324.7 million, with a median of $280.6 million in 2025.
  • In the last 5 years, Pliant Therapeutics' Equity Average surged by 24050.05% in 2023 and then plummeted by 4307.54% in 2025.
  • Pliant Therapeutics' Equity Average (Quarter) stood at $209.7 million in 2021, then soared by 55.03% to $325.2 million in 2022, then skyrocketed by 50.17% to $488.3 million in 2023, then plummeted by 33.45% to $325.0 million in 2024, then tumbled by 35.32% to $210.2 million in 2025.
  • Its last three reported values are $210.2 million in Q3 2025, $238.6 million for Q2 2025, and $280.6 million during Q1 2025.